Key Client Fiduciary Advisors LLC Has $364,000 Stock Position in Becton, Dickinson and Company (NYSE:BDX)

Key Client Fiduciary Advisors LLC lessened its holdings in Becton, Dickinson and Company (NYSE:BDX) by 9.2% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,557 shares of the medical instruments supplier’s stock after selling 158 shares during the period. Key Client Fiduciary Advisors LLC’s holdings in Becton, Dickinson and Company were worth $364,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also modified their holdings of BDX. Addenda Capital Inc. lifted its holdings in Becton, Dickinson and Company by 17.4% in the 2nd quarter. Addenda Capital Inc. now owns 35,363 shares of the medical instruments supplier’s stock worth $8,265,000 after purchasing an additional 5,240 shares during the last quarter. ORG Partners LLC raised its position in shares of Becton, Dickinson and Company by 2,250.8% in the second quarter. ORG Partners LLC now owns 1,387 shares of the medical instruments supplier’s stock valued at $319,000 after purchasing an additional 1,328 shares during the period. PineStone Asset Management Inc. lifted its stake in shares of Becton, Dickinson and Company by 141.6% in the second quarter. PineStone Asset Management Inc. now owns 1,345,873 shares of the medical instruments supplier’s stock worth $314,544,000 after buying an additional 788,735 shares during the last quarter. Riverview Trust Co boosted its holdings in shares of Becton, Dickinson and Company by 5.9% during the 2nd quarter. Riverview Trust Co now owns 1,257 shares of the medical instruments supplier’s stock worth $294,000 after buying an additional 70 shares during the period. Finally, Bill Few Associates Inc. grew its stake in Becton, Dickinson and Company by 4.0% in the 2nd quarter. Bill Few Associates Inc. now owns 7,389 shares of the medical instruments supplier’s stock valued at $1,727,000 after buying an additional 285 shares during the last quarter. Institutional investors and hedge funds own 86.97% of the company’s stock.

Becton, Dickinson and Company Price Performance

Shares of Becton, Dickinson and Company stock traded down $2.20 during trading on Wednesday, hitting $234.08. 1,075,025 shares of the company’s stock traded hands, compared to its average volume of 1,446,660. The company has a market cap of $67.65 billion, a PE ratio of 51.56, a PEG ratio of 2.06 and a beta of 0.42. The firm’s fifty day moving average price is $233.42 and its 200 day moving average price is $236.23. Becton, Dickinson and Company has a twelve month low of $218.75 and a twelve month high of $283.50. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.85 and a quick ratio of 0.97.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings data on Thursday, August 1st. The medical instruments supplier reported $3.50 earnings per share for the quarter, beating analysts’ consensus estimates of $3.31 by $0.19. Becton, Dickinson and Company had a return on equity of 14.49% and a net margin of 7.13%. The company had revenue of $4.99 billion for the quarter, compared to the consensus estimate of $5.08 billion. During the same period in the previous year, the business earned $2.96 earnings per share. The company’s quarterly revenue was up 2.3% on a year-over-year basis. Analysts forecast that Becton, Dickinson and Company will post 13.06 earnings per share for the current year.

Becton, Dickinson and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, September 30th. Shareholders of record on Monday, September 9th will be paid a dividend of $0.95 per share. The ex-dividend date of this dividend is Monday, September 9th. This represents a $3.80 annualized dividend and a yield of 1.62%. Becton, Dickinson and Company’s dividend payout ratio is currently 83.70%.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on the stock. The Goldman Sachs Group initiated coverage on shares of Becton, Dickinson and Company in a report on Thursday, May 30th. They set a “buy” rating and a $274.00 price target for the company. Stifel Nicolaus raised their target price on Becton, Dickinson and Company from $270.00 to $280.00 and gave the company a “buy” rating in a report on Friday, July 26th. Evercore ISI cut their price target on Becton, Dickinson and Company from $290.00 to $285.00 and set an “outperform” rating for the company in a report on Tuesday, July 2nd. StockNews.com upgraded shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research note on Thursday, August 8th. Finally, Barclays boosted their target price on shares of Becton, Dickinson and Company from $305.00 to $312.00 and gave the stock an “overweight” rating in a research report on Monday, May 6th. One investment analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Becton, Dickinson and Company currently has an average rating of “Moderate Buy” and a consensus target price of $279.50.

Insider Buying and Selling at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, SVP Thomas J. Spoerel sold 300 shares of the business’s stock in a transaction dated Monday, June 10th. The shares were sold at an average price of $239.31, for a total value of $71,793.00. Following the transaction, the senior vice president now directly owns 1,976 shares in the company, valued at $472,876.56. The transaction was disclosed in a document filed with the SEC, which is available through this link. Company insiders own 0.31% of the company’s stock.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.